Recent Company News

• 10:53 PM ET May 08, 2025
  

  Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

• 07:26 AM ET May 07, 2025
  

  Genenta and Anemocyte announce collaboration for manufacturing of starting materials for cell-based therapies ($4.25, 0.00)

• 09:36 AM ET Mar 19, 2025
  

  Genenta announces €20M financing to expand pipeline and February cutoff data of Brain Tumor trial ($3.95, +0.15)

• 04:22 PM ET Dec 20, 2024
  

  Genenta Science amends previously disclosed ATM agreement; increases total amount to $29.7M, adds Rodman & Renshaw as agent ($5.19, 0.00)

• 10:13 AM ET Oct 10, 2024
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (119 total)

• 06:32 AM ET Oct 02, 2024
  

  Genenta secures approval for trial for metastatic renal cell cancer in Italy ($4.08, 0.00)

• 05:10 PM ET Apr 26, 2024
  

  Genenta Science enters ATM sales agreement of up to $16.4M of ADS with Capital One Securities and Virtu Americas - 424B5 ($2.59, 0.00)

• 04:33 PM ET Apr 09, 2024
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:30 AM ET Apr 09, 2024
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:50 AM ET Apr 09, 2024
  

  Rodman & Renshaw initiates GNTA, INAB, IPSC